| Business Summary | | Immucor
Inc.
develops,
manufactures
and
sells
a
complete
line
of
reagents
and
automated
systems
used
primarily
by
hospitals,
clinical
laboratories
and
blood
banks
in
a
number
of
tests
performed
to
detect
and
identify
certain
properties
of
the
cell
and
serum
components
of
human
blood
prior
to
blood
transfusion.
During
fiscal
1999,
the
Company
implemented
its
strategic
plans
to
consolidate
the
United
States
blood
bank
market,
leaving
Immucor
and
Ortho
Clinical
Diagnostics
as
the
only
two
companies
offering
a
complete
line
of
blood
banking
reagents
in
the
United
States,
and
to
strengthen
Immucor's
direct
presence
in
Europe
and
Canada.
Immucor
is
part
of
the
immunohematology
industry,
which
generally
seeks
to
prevent
or
cure
certain
diseases
or
conditions
through
the
transfusion
of
blood
and
blood
components. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Immucor,
Inc.
develops,
manufactures
and
sells
a
complete
line
of
reagents
and
automated
systems
used
primarily
by
hospitals,
clinical
laboratories
and
blood
banks
to
detect
and
identify
properties
in
the
human
blood.
For
the
nine
months
ended
2/28/01,
revenues
fell
13%
to
$50.8
million.
Net
loss
totalled
$6.7
million
vs.
an
income
of
$3.5
million.
Results
reflect
delays
in
customer
accepting
instruments
and
a
$3.3
million
loss
on
impairment
of
goodwill. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Edward Gallup, 61 Chairman,
Pres and CEO | $268K | Patrick Waddy, 43 Pres
of Dominion Biologicals Limited and European Fin. Director | 88K | Gioacchino De Chirico, 47 Director;
Director of European Operations and Pres of Immucor Italia S.r.l. | 214K | Ralph Eatz, 56 Sr.
VP of Operations | 250K | Steven Ramsey, 51 VP,
CFO, Sec. | 186K | Dollar amounts are as of 31-May-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|